Celltrion

In 1999, Nexol, Inc. (now Celltrion Healthcare Co., Ltd.) was founded as a global business management consulting firm. In 2002, Celltrion, Inc. was founded as a biopharmaceutical company. In 2008, Nexol and Celltrion established a global distribution agreement. In 2009, distribution channels were established in America, Oceania, Europe (Hospira) and Nexol, Inc. renamed as Celltrion Healthcare Co., Ltd. In 2010, distribution channels were established in Japan (Nippon Kayaku), Commonwealth of Independent States (CIS), Eastern Europe, and the Middle East (Egis). In 2013, distribution channels were added in Europe (Mundipharma, Biogaran, and Kern). On September 30, 2024, Celltrion completed the establishment of its oversees corporation in Vietnam. 22 Oct. 2024. Celltrion secured a 100.4 billion won ($72.8 million) deal for contract development and manufacturing (CDMO) with TEVA Pharmaceuticals International for the migraine treatment Ajovy. In November 2024, Celltrion acquired iQone Healthcare Switzerland, a pharmaceutical company for around 30 billion won ($21 million). This move will help its expansion in Europe. In August 2025, Celltrion was announced to have made a bid of $504.3 million for Eli Lilly's BB50 Branchburg, NJ site. ==Products==

The company's products are manufactured at mammalian cell culture facilities designed and built to comply with the United States FDA’s cGMP, and the European Medicines Agency’s GMP standards. Inline product Remsima (infliximab) is a biosimilar monoclonal antibody against tumor necrosis factor alpha (TNF-α), approved by the European Medicines Agency (EMA) for treatment of: • rheumatoid arthritis, • adult Crohn's disease, • pediatric Crohn's disease, • ulcerative colitis, • pediatric ulcerative colitis, • ankylosing spondylitis, • psoriatic arthritis, and • psoriasis. In 2012 Remsima was approved by the Republic of Korea's Ministry of Food and Drug Safety (MFDS), previously known as Korea Food and Drug Administration and in 2013 it became the world's first biosimilar monoclonal antibody (mAb) approved by the EMA. Truxima (previously known as CT-P10) is the first biosimilar of the reference monoclonal antibody rituximab that targets CD20 molecule primarily found on the surface of B-cells. Its target indications are rheumatoid arthritis, non-Hodgkin lymphoma and chronic lymphocytic leukemia. It was approved by the EMA in February 2017. == Corporate Governance ==